Navigation Links
AMP opposes exclusive licensing of NIH proteomics patent
Date:11/22/2011

Bethesda, MD The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency. AMP's written remarks were submitted to NIH in response to a request for comments in the Federal Register Notice entitled, "Prospective Grant of Exclusive License: The Development of a Companion Diagnostic Kit for Predicting Therapeutic Efficacy of Anti-Cancer Agents." The proposed license grants exclusive worldwide rights to use the relationships between levels of three proteins, PTEN, Akt, and mTOR and cancers of the breast, lung, and kidney. Under the terms of the prospective agreement, the licensor could provide laboratory test services and/or sell test kits.

"The submitted patent application encompasses essentially all methods and techniques that allow practical use of the claimed biological relationships. The breadth of this patent application renders exclusive licensing of even a subset of the proteincancer associations claimed contrary to the public interest," stated Roger D. Klein, MD, JD, Chair of the AMP Professional Relations Committee. "No one company should be permitted to monopolize medical information in this way."

In its comments, AMP set forth the reasons the organization believes NIH's proposed exclusive license fails to meet the regulatory constraints on exclusive licensing of federally owned inventions as set forth in 35 U.S.C. 209(a) and 37 C.F.R. 404.737 C.F.R. 404.7. According to U.S. law, such a license must serve the best interests of the public; must be a "reasonable and necessary" incentive for the attraction of investments required to bring the invention to practical application; and must not lessen competition. Further, practical application of the invention must be unlikely under a nonexclusive license, and the scope of exclusivity cannot be broader than is necessary to bring the invention to practical application. AMP believes the proposed license does not meet any of these criteria.

"This patent application claims a virtually unlimited swathe of protein diagnostics, dramatically inhibiting the growth of potential diagnostic assays and methods, while substantially increasing the costs of and decreasing patient access to those tests that do manage to enter medical practice. By granting an exclusive license for any of the protein-cancer relationships claimed in this patent application, NIH would stifle the practice of medicine, limit patients' access to second opinion tests and discourage innovation in this area," added Dr. Klein.

As a general principle, AMP opposes exclusive licensing of patents on governmental inventions that do not clearly advance the public interest. AMP believes that such licenses, in the rare circumstances in which they are granted, should be narrowly targeted and not reach beyond the extent necessary to ensure commercialization. Importantly, for inventions in which clinical laboratory testing is potentially impacted, sublicenses for confirmatory testing that include reasonable royalty rates and the right to use alternative test methodologies should generally be mandated.


'/>"/>
Contact: Don Hunt
dhunt@lambert-edwards.com
616-233-0500
Association for Molecular Pathology
Source:Eurekalert

Related biology news :

1. New asthma research opposes current drug treatment, says UH prof
2. FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract
3. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
4. GenWay Biotech obtains exclusive rights to AMDLs DR-70 cancer test in US and Canada
5. Ardiem Medical obtains non-exclusive license for neuromodulation devices
6. University of Nevada, Reno, professor receives exclusive American Fisheries Award of Excellence
7. Dow Agrosciences licenses exclusive novel crop enhancement technology
8. Isogenic cell models for cancer research exclusively licensed to Horizon Discovery
9. Rare Andean cat no longer exclusive to the Andes
10. Case Western Reserve and NeoProteomics announce exclusive option
11. Encap agrees colonic drug delivery licensing deal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... Nov. 30, 2016 Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Nebraska . The 15,200 square foot state-of-the-art facility ... 2016 and brings the total number of BPC,s plasma ... Carlisle , BPC,s Chief Executive Officer said "We are ...
(Date:11/30/2016)... DIEGO and BEIJING , ... a leading commercial provider of genomic services and solutions ... announced today that it has completed a USD $75 ... Merchants Bank Co., Ltd.,s CMB International Capital Management ( ... Innovation Investment Management Co., Ltd. ("SDIC Innovation") and Shanghai ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in ... implications of the latest FDA guidance on pharmaceutical cocrystals as drug substance . ... MA. , The event follows the successful November 15th event that took ...
(Date:11/30/2016)... ... November 30, 2016 , ... With growth rates averaging more than ... years and look forward to continuing their expansion in their new office space. The ... has been traditionally favoured by the creative industries, so Random42 Scientific Communication will fit ...
Breaking Biology Technology: